The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician’s choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769).
 
Tiffany Traina
Consulting or Advisory Role - Aktis Oncology; AstraZeneca; BioNTech SE; Daiichi Sankyo; Ellipses Pharma; Exact Sciences; Genentech/Roche; Gilead Sciences; GlaxoSmithKline; Merck; Pfizer; Stemline Therapeutics; Tersera; Veracyte
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Genentech/Roche (Inst); Pfizer (Inst)
 
Yuan Chen
No Relationships to Disclose
 
Katia Khoury
No Relationships to Disclose
 
Hope Rugo
Honoraria - Chugai Pharma; Mylan/Viatris
Consulting or Advisory Role - Bristol Meyer; Napo Pharmaceuticals; Sanofi
Research Funding - Ambryx (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Hoffmann-La Roche AG/Genentech, Inc (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Pfizer (Inst); Stemline Therapeutics (Inst)
 
Erica Mayer
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis
 
Yara Abdou
Honoraria - Cancer Expert Now; Clinical Care Options; Clinical Care Options; MJH Associates; WebMD/Medscape
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - Haystack Oncology (Inst); Natera (Inst)
(OPTIONAL) Uncompensated Relationships - Exact Sciences
 
Michelle Melisko
Stock and Other Ownership Interests - Merrimack (I)
Consulting or Advisory Role - Genentech
Speakers' Bureau - AstraZeneca (I); Daiichi Sankyo/Astra Zeneca (I); Gilead Sciences (I)
Research Funding - DAEHWA Pharmaceutical (Inst); OBI Pharma (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Multiple patents related to immunoliposomal drugs being studied and potentially brought to market by Merrimack (I)
Expert Testimony - GlaxoSmithKline
 
Fresia Pareja
Consulting or Advisory Role - AstraZeneca; MultiplexDx
 
Britta Weigelt
Employment - AstraZeneca (I)
Stock and Other Ownership Interests - Repare Therapeutics (I)
Consulting or Advisory Role - Bain Capital Life Sciences (I); PAIGE (I); Repare Therapeutics (I); SAGA Diagnostics (I); Volition RX (I)
Research Funding - Repare Therapeutics (Inst); SAGA Diagnostics (Inst)
 
Sarat Chandarlapaty
Stock and Other Ownership Interests - Totus Medicines
Consulting or Advisory Role - AstraZeneca/MedImmune; Casdin Capital; Daiichi Sankyo; Hexagon; Lilly; Novartis; Prelude Therapeutics; SAGA Diagnostics
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for (1) targeting mutant ER with ER PROTACS and (2) targeting CDK4/6 with CDK4/6 PROTACS (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Nicholas Turner
Consulting or Advisory Role - AstraZeneca; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Guardant Health; Inivata; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Relay Therapeutics; Repare Therapeutics; Roche
Research Funding - AstraZeneca (Inst); Guardant Health (Inst); Inivata (Inst); InVitae (Inst); Merck Sharpe and Dohme (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst); Roche (Inst)
 
Joshua Lang
Consulting or Advisory Role - 4D Pharma; 4D Pharma; Arvinas; AstraZeneca; Foundation Medicine; Gilead Sciences; Immunomedics; Janssen; Macrogenics; Pfizer; Pfizer/Astellas; Pfizer/Myovant; Sanofi
Research Funding - Agensys (Inst); Arvinas (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Medivation (Inst)
Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.
 
Marina Sharifi
Research Funding - Novartis (Inst)
 
Suzanne Conzen
Patents, Royalties, Other Intellectual Property - A GR antagonist methods patent owned by the University of Chicago that I am a co-Inventor on is licensed to Corcept Therapeutics
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics; Summit Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics